RECRUITING

Tissue Collection for Studies of Lymph Cancer

Talk to us

Conditions

Hodgkin DiseaseLymphoma, Non-HodgkinMultiple MyelomaLymphomatoid GranulomatosisLeukemia-Lymphoma, Adult T-CellDeveloping Novel Treatment ApproachesDeveloping Therapeutic AgentsAnalysis of Genetic and Genomic BiologyNew Prognostic and Diagnostic ModelsAnalysis of Cellular and Molecular BiologyNatural History

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: \- Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These conditions include multiple myeloma, different types of lymphoma, and adult leukemia/lymphoma. The samples collected will include blood, urine, bone marrow, and tumor and skin tissue. Objectives: \- To collect tissue samples to study different types of lymph cancer. Eligibility: \- Individuals at least 18 years of age who have a lymphoid cancer or precancer condition. Design: * Participants will be screened with a physical exam and medical history. * Different samples will be collected for study. Blood samples will be collected at the initial testing. More blood samples will be collected at different treatment points. Other liquid samples include urine, bone marrow, and any abnormal fluid. Tumor tissue and skin tissue biopsies will also be collected for study. * Treatment will not be provided as part of this study.

Official Title

Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol

Quick Facts

Study Start:2012-09-21
Study Completion:N/A
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01676805

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy, including multiple myeloma, B-cell and T-cell lymphomas: including but not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL).
  2. * Confirmation of pathological diagnosis is required from the Laboratory of Pathology, NCI. Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care or required testing on an NIH research protocol will be used for diagnosis.
  3. * Age \>= 18 years of age
  4. * ECOG performance 0-2
  5. * Ability of patient or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document NOTE: Patients enrolling with a LAR must be co-enrolled on another study.
  6. * Hemoglobin \>= 10 mg/dL and platelet count \> 75 K/uL
  7. * Weight greater than 25 kg
  8. * HIV negative
  9. * Prothrombin Time - within normal limits
  10. * Partial Thromboplastin Time - within normal limits
  11. * Medically indicated central line in place or adequate peripheral venous access
  1. * Pregnant individuals will not be eligible.
  2. * Active symptomatic major organ disorder that would increase the risk of biopsy or apheresis, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.
  3. * Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.

Contacts and Locations

Study Contact

NCIMO Referral Office
CONTACT
(888) 624-1937
ncimo_referrals@mail.nih.gov
Mark J Roschewski, M.D.
CONTACT
(240) 760-6183
mark.roschewski@nih.gov

Principal Investigator

Mark J Roschewski, M.D.
PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Cancer Institute (NCI)

  • Mark J Roschewski, M.D., PRINCIPAL_INVESTIGATOR, National Cancer Institute (NCI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2012-09-21
Study Completion DateN/A

Study Record Updates

Study Start Date2012-09-21
Study Completion DateN/A

Terms related to this study

Keywords Provided by Researchers

  • Developing Novel Treatment Approaches
  • Developing Therapeutic Agents
  • Analysis of Genetic and Genomic Biology
  • New Prognostic and Diagnostic Models
  • Analysis of Cellular and Molecular Biology
  • Natural History

Additional Relevant MeSH Terms

  • Hodgkin Disease
  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • Lymphomatoid Granulomatosis
  • Leukemia-Lymphoma, Adult T-Cell